Share
Dr Köser is a Consultant with TB Alliance, New York, USA; Becton Dickinson, Sparks, MD, USA and the Foundation for Innovative New Diagnostics, Geneva, Switzerland.
He is a Visiting Scientist at the Department of Genetics, University of Cambridge and a Research Associate at Wolfson College, University of Cambridge.
His work for Becton Dickinson involves a collaboration with Janssen and Thermo Fisher Scientific. He is collaborating with PZA Innovation. He has worked as a consultant for QuantuMDx, the Stop TB Partnership, the World Health Organization (WHO) Global TB Programme, and the WHO Regional Office for Europe.
His main interest lies in bringing modern microbiological principles to defining susceptibility and resistance to anti-TB agents. This work revealed that the WHO breakpoints for several first- and second-line antibiotics had been too high, resulting in the systematic misclassification of resistant strains as susceptible. He is working closely with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and drug developers to avoid these shortcomings for new agents.
